ARLG at IDWeek 2021

Make the most of IDWeek 2021! From Sept. 29 – Oct. 3, ARLG’s top leaders and experts will be discussing the latest AMR topics. Use the guide below to plan your conference sessions.

ARLG IDWeek 2021 Sessions

DayTimeSession TitlePresentation TitleModeratorsSpeakers
Sept. 29
4:00 - 5:15 p.m. Chasing the Sun: CTS-06 - COVID-19 IDSA Rapid Living Guidelines: Celebrations and ChallengesCOVID-19 diagnostic testing guidelinesKim Hanson
Sept. 297:00 - 8:00p.m.Chasing the Sun: CTS-08 - COVID-19 Update in JapanYohei Doi
Sept. 3011:00 a.m. - 12:15 p.m.04 - Case-based Guidelines SessionAntimicrobial Resistant Gram-Negative Infections: A Case Based ApproachPranita Tamma
Sept. 3011:00 a.m. - 12:15 p.m.04 - Case-based Guidelines SessionMolecular Diagnostics and Antigen Testing for COVID-19Angela Caliendo
Sept. 3011:00 a.m. - 12:15 p.m.05 - Diagnostic Clinical CasesChris Doern (panelist)
Sept. 3011:00a.m. - 12:15p.m. 12 - Hot issues in Enterococcus faecalis bacteremia/endocarditis (IE)Jose Miro
Sept. 3012:30 - 1:45 p.m.19 - Even More Bad Bugs (with Limited Drugs)Difficult-to-treat Resistance (DTR) Pseudomonas aeruginosaJessica Howard-Anderson
Sept. 3012:30 - 1:45 p.m.21 - Cardiovascular implantable electronic device (CIED) infectionsMicrobiological Diagnosis: Role of Advanced DiagnosticsJose MiroRobin Patel
Sept. 3012:30 - 1:45 p.m.26 - New Approaches to the Diagnosis of Lower Respiratory Tract InfectionsNext-generation Sequencing Approaches to Lower Respiratory Tract InfectionsPatricia (Trish) Simner
Sept. 303:45 - 5:00 p.m.43 – What’s New with VRETreatment of VRE Bacteremia: What You Need to KnowJulia MessinaJose Munita
Sept. 305:15 - 6:30 p.m.53 - Clinical Controversies in S. aureus BacteremiaOptimal Dosing of Antibiotics for S.aureus Bacteremia in Specific PopulationsTom HollandAmit Pai
Sept. 305:15 - 6:30 p.m.56 - Leading Teams During a CrisisManaging & Maintaining PrioritiesEbbing Lautenbach
Oct. 110:00 - 11:15 a.m.61 - Do breakpoints matter? The fungal storyBreakpoints in YeastMariana Castanheira
Oct. 111:30 a.m. - 12:45 p.m.750 - Challenging cases in Infectious DiseasesHenry Chambers (interactive moderator)
Oct. 111:30 a.m. - 12:45 p.m.79 - Top Practice-Changing Papers on Transplant IDTop Practice-changing Papers in Solid Organ TransplantJudith Anesi
Oct. 111:30a.m. - 12:45p.m85 - Public-private partnerships to revive future antibiotic development and accessYohei Doi
Oct. 12:45 - 4:00 p.m.90 - Therapeutic options for MDR gram-negativesYohei Doi (interactive moderator)David van Duin (panelist)
Oct. 12:45 - 4:00 p.m.92 - Successes in Outpatient StewardshipSara Cosgrove
Oct. 12:45 - 4:00p.m. 95 - Big Beasts of Skin & Soft Tissue InfectionsGram-Positive Necrotizing Soft Tissue InfectionsHenry Chambers
Oct. 12:45 - 4:00p.m. 101 - Update on natural and Prosthetic Vascular Graft InfectionsJose Miro
Oct. 12:45 - 4:00 p.m.102 - What's New in Orthopedic Infections: Bone Appetit!Going Viral: Phage Therapy for Orthopedic InfectionsGina Suh
Oct. 14:15 - 5:30p.m. 110 – Infectious Disease Consulting for Businesses During COVID-19: Tales from the Front LineCOVID-19 Consulting for the Entertainment IndustryAnthony Harris
Oct. 210:00 - 11:15 a.m.
127 - Pathogen-specific clinical trials: promise and practical considerationsGram-Negative Trials: Lessons LearnedYohei Doi Thomas Lodise
Oct. 21:15 - 3:00 p.m.133 - Clinical Trials That May Change Your PracticeJessica Howard-Anderson, Tom Holland

ARLG IDWeek 2021 Posters

NumberTitleAuthors
1219Unfavorable Clinical Outcomes with Polymyxins Compared to Ceftolozane/Tazobactam for the Treatment of Carbapenem-Resistant Pseudomonas aeruginosaHoward-Anderson J, Earley M, Hamasaki T, Bower CW, Smith G, van Duin D, Evans S, Jacob JT
1094Determination of Plasma Protein Binding of DalbavancinTurner NA, Xu A, Zaharoff S, Holland TL, Lodise TP on behalf of the Antibacterial Resistance Leadership Group